Rare Disease Trial, Recruiting NCT05046444 Sponsor: Munich Leukemia Laboratory Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT05046444
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been tested for a possible blood disorder, but your diagnosis is still unclear after standard tests
  • Your illness has followed an unexpected or unusual pattern compared to what doctors would normally expect
  • Your condition has not responded to treatment in the typical way, or has been unusually difficult to treat
  • You have been found to have more than one blood condition happening at the same time
  • You have developed a secondary or rare cancer that may be related to a previous treatment, and it has been difficult to diagnose or manage
  • Your current test results are not giving doctors a clear enough picture of your condition or how it is behaving
  • You are at least 18 years old
  • Your blood or bone marrow sample contains at least 20% cancer cells
  • You are willing and able to give your written consent to take part

Who may not be able to join:

  • Your sample is not suitable for modern testing methods or does not pass the initial quality checks (confirm with trial site)
  • Your sample was collected or stored incorrectly — for example, using the wrong preservative, or it was damaged by being frozen and thawed or exposed to high temperatures
  • Your sample does not contain enough cancer cells (less than 20%) to allow standard diagnostic testing to be carried out safely

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 (0)89 99017-100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Munich Leukemia Laboratory
Registry
ClinicalTrials.gov
Start date
19 January 2022
Est. completion
31 August 2025

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

sequencing only versus gold standard diagnosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov